ClaudineIsaacsMDFRCPC
Oncology • Washington, DCBreast Cancer, Cancer Genetics/Cancer Risk Assessment
Professor, Medicine, MedStar Georgetown University Hospital, Georgetown University Medical Center
Dr. Isaacs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd NW
Washington, DC 20007Phone+1 202-444-2223
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1993
MedStar Health/Georgetown-Washington Hospital CenterFellowship, Hematology and Medical Oncology, 1993
McGill University Faculty of MedicineClass of 1987
Certifications & Licensure
DC State Medical License 1993 - 2024
MD State Medical License 2011 - 2014- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2022
- Top Doctors: Washington DC Washingtonian Magazine, 2012, 2015-2022
- America's Top Doctors for Cancer Castle Connolly, 2005-2022
- Join now to see all
Clinical Trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2024-12-07 - Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace
Breast Cancer Research and Treatment. 2024-12-03 - 6 citationsDatopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
Journal Articles
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerRita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Other
- Genetic testing for hereditary breast and ovarian cancer syndromeIsaacs C, Peshkin BN, Fletcher SW
http://www.uptodate.com/contents/genetic-testing-for-hereditary-breast-and-ovarian-cancer-syndrome
UpToDate, Wolters Kluwer Health - 2012-08-13 - Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutationsIsaacs C, Peshkin BN, Fletcher SW
http://www.uptodate.com/contents/management-of-hereditary-breast-and-ovarian-cancer-syndrome-and-pat
UpToDate, Wolters Kluwer Health - 2013-04-10 - Characteristics of hereditary breast and ovarian cancer syndromesIsaacs C, Peshkin BN
http://www.uptodate.com/contents/characteristics-of-hereditary-breast-and-ovarian-cancer-syndromes
UpToDate, Wolters Kluwer Health - 2012-12-11 - Join now to see all
Authored Content
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020
Press Mentions
Anti-PD-1/Anti-LAG-3 Combination Highly Effective in HER2-Negative Breast CancerDecember 20th, 2022- High Rates of pCR with Novel Neoadjuvant Combination for Breast CancerDecember 11th, 2022
- Breast Cancer Myths vs. Facts | VerifyOctober 28th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
